Browse TERT

Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus, nucleolus Nucleus, nucleoplasm. Nucleus. Chromosome, telomere. Cytoplasm. Nucleus, PML body. Note=Shuttling between nuclear and cytoplasm depends on cell cycle, phosphorylation states, transformation and DNA damage. Diffuse localization in the nucleoplasm. Enriched in nucleoli of certain cell types. Translocated to the cytoplasm via nuclear pores in a CRM1/RAN-dependent manner involving oxidative stress-mediated phosphorylation at Tyr-707. Dephosphorylation at this site by SHP2 retains TERT in the nucleus. Translocated to the nucleus by phosphorylation by AKT.
Domain PF00078 Reverse transcriptase (RNA-dependent DNA polymerase)
PF12009 Telomerase ribonucleoprotein complex - RNA binding domain
Function

Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoenzyme complex whose main activity is the elongation of telomeres by acting as a reverse transcriptase that adds simple sequence repeats to chromosome ends by copying a template sequence within the RNA component of the enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The catalytic cycle involves primer binding, primer extension and release of product once the template boundary has been reached or nascent product translocation followed by further extension. More active on substrates containing 2 or 3 telomeric repeats. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. Modulates Wnt signaling. Plays important roles in aging and antiapoptosis.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0000723 telomere maintenance
GO:0001172 transcription, RNA-templated
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0006278 RNA-dependent DNA biosynthetic process
GO:0007004 telomere maintenance via telomerase
GO:0007346 regulation of mitotic cell cycle
GO:0007568 aging
GO:0007569 cell aging
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010608 posttranscriptional regulation of gene expression
GO:0010721 negative regulation of cell development
GO:0010827 regulation of glucose transport
GO:0010828 positive regulation of glucose transport
GO:0010833 telomere maintenance via telomere lengthening
GO:0014009 glial cell proliferation
GO:0014013 regulation of gliogenesis
GO:0014014 negative regulation of gliogenesis
GO:0014812 muscle cell migration
GO:0014909 smooth muscle cell migration
GO:0014910 regulation of smooth muscle cell migration
GO:0014911 positive regulation of smooth muscle cell migration
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0016055 Wnt signaling pathway
GO:0016246 RNA interference
GO:0016441 posttranscriptional gene silencing
GO:0016458 gene silencing
GO:0022616 DNA strand elongation
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030335 positive regulation of cell migration
GO:0030422 production of siRNA involved in RNA interference
GO:0031047 gene silencing by RNA
GO:0031050 dsRNA fragmentation
GO:0031647 regulation of protein stability
GO:0032092 positive regulation of protein binding
GO:0032200 telomere organization
GO:0032768 regulation of monooxygenase activity
GO:0032770 positive regulation of monooxygenase activity
GO:0033002 muscle cell proliferation
GO:0034502 protein localization to chromosome
GO:0034504 protein localization to nucleus
GO:0035194 posttranscriptional gene silencing by RNA
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0038034 signal transduction in absence of ligand
GO:0040017 positive regulation of locomotion
GO:0040029 regulation of gene expression, epigenetic
GO:0042063 gliogenesis
GO:0042303 molting cycle
GO:0042633 hair cycle
GO:0042634 regulation of hair cycle
GO:0042635 positive regulation of hair cycle
GO:0043331 response to dsRNA
GO:0043393 regulation of protein binding
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045787 positive regulation of cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0046323 glucose import
GO:0046324 regulation of glucose import
GO:0046326 positive regulation of glucose import
GO:0046686 response to cadmium ion
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050768 negative regulation of neurogenesis
GO:0050999 regulation of nitric-oxide synthase activity
GO:0051000 positive regulation of nitric-oxide synthase activity
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051272 positive regulation of cellular component movement
GO:0051341 regulation of oxidoreductase activity
GO:0051353 positive regulation of oxidoreductase activity
GO:0051402 neuron apoptotic process
GO:0051961 negative regulation of nervous system development
GO:0060147 regulation of posttranscriptional gene silencing
GO:0060149 negative regulation of posttranscriptional gene silencing
GO:0060249 anatomical structure homeostasis
GO:0060251 regulation of glial cell proliferation
GO:0060253 negative regulation of glial cell proliferation
GO:0060290 transdifferentiation
GO:0060966 regulation of gene silencing by RNA
GO:0060967 negative regulation of gene silencing by RNA
GO:0060968 regulation of gene silencing
GO:0060969 negative regulation of gene silencing
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0070198 protein localization to chromosome, telomeric region
GO:0070199 establishment of protein localization to chromosome
GO:0070200 establishment of protein localization to telomere
GO:0070482 response to oxygen levels
GO:0070918 production of small RNA involved in gene silencing by RNA
GO:0070920 regulation of production of small RNA involved in gene silencing by RNA
GO:0070997 neuron death
GO:0071359 cellular response to dsRNA
GO:0071407 cellular response to organic cyclic compound
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071897 DNA biosynthetic process
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0072577 endothelial cell apoptotic process
GO:0090065 regulation of production of siRNA involved in RNA interference
GO:0090068 positive regulation of cell cycle process
GO:0090342 regulation of cell aging
GO:0090344 negative regulation of cell aging
GO:0090398 cellular senescence
GO:0090399 replicative senescence
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0198738 cell-cell signaling by wnt
GO:1900087 positive regulation of G1/S transition of mitotic cell cycle
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1900368 regulation of RNA interference
GO:1900369 negative regulation of RNA interference
GO:1901099 negative regulation of signal transduction in absence of ligand
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901342 regulation of vasculature development
GO:1901987 regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902570 protein localization to nucleolus
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902808 positive regulation of cell cycle G1/S phase transition
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903618 regulation of transdifferentiation
GO:1903620 positive regulation of transdifferentiation
GO:1903704 negative regulation of production of siRNA involved in RNA interference
GO:1903829 positive regulation of cellular protein localization
GO:1904018 positive regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904705 regulation of vascular smooth muscle cell proliferation
GO:1904707 positive regulation of vascular smooth muscle cell proliferation
GO:1904738 vascular associated smooth muscle cell migration
GO:1904749 regulation of protein localization to nucleolus
GO:1904751 positive regulation of protein localization to nucleolus
GO:1904752 regulation of vascular associated smooth muscle cell migration
GO:1904754 positive regulation of vascular associated smooth muscle cell migration
GO:1904837 beta-catenin-TCF complex assembly
GO:1990874 vascular smooth muscle cell proliferation
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000147 positive regulation of cell motility
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
GO:2000648 positive regulation of stem cell proliferation
GO:2000772 regulation of cellular senescence
GO:2000773 negative regulation of cellular senescence
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
Molecular Function GO:0000049 tRNA binding
GO:0001221 transcription cofactor binding
GO:0001223 transcription coactivator binding
GO:0003720 telomerase activity
GO:0003721 telomerase RNA reverse transcriptase activity
GO:0003964 RNA-directed DNA polymerase activity
GO:0003968 RNA-directed RNA polymerase activity
GO:0008134 transcription factor binding
GO:0016779 nucleotidyltransferase activity
GO:0034061 DNA polymerase activity
GO:0034062 RNA polymerase activity
GO:0042162 telomeric DNA binding
GO:0070034 telomerase RNA binding
Cellular Component GO:0000333 telomerase catalytic core complex
GO:0000781 chromosome, telomeric region
GO:0000782 telomere cap complex
GO:0000783 nuclear telomere cap complex
GO:0000784 nuclear chromosome, telomeric region
GO:0005697 telomerase holoenzyme complex
GO:0005759 mitochondrial matrix
GO:0009295 nucleoid
GO:0016604 nuclear body
GO:0016605 PML body
GO:0030880 RNA polymerase complex
GO:0031379 RNA-directed RNA polymerase complex
GO:0032993 protein-DNA complex
GO:0042645 mitochondrial nucleoid
GO:0044454 nuclear chromosome part
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0098687 chromosomal region
GO:1990572 TERT-RMRP complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1640170: Cell Cycle
R-HSA-73886: Chromosome Maintenance
R-HSA-180786: Extension of Telomeres
R-HSA-201722: Formation of the beta-catenin
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-171319: Telomere Extension By Telomerase
R-HSA-157579: Telomere Maintenance
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TERT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TERT and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27481844Non-Small Cell Lung CarcinomaPromote immunity (T cell function); essential for immunotherapyTelomerase is a prototype-shared tumor Ag and represents an attractive target for anticancer immunotherapy. We have previously described promiscuous and immunogenic HLA-DR-restricted peptides derived from human telomerase reverse transcriptase (hTERT) and referred as universal cancer peptide (UCP). In nonsmall cell lung cancer, the presence of spontaneous UCP-specific CD4 T cell responses increases the survival of chemotherapy-responding patients. Altogether, our findings provide a novel mechanism of tumor-specific CD4 T cell activation and will be useful for the development of novel cancer immunotherapies that harness CD4 T cells.
23641014Adult T-Cell Leukemia/LymphomaPromote immunity (T cell function); essential for immunotherapyHere we demonstrated for the first time that human telomerase reverse transcriptase (hTERT) is a promising therapeutic target for ATL, and we developed a novel redirected T-cell-based immunotherapy targeting hTERT. hTERT messenger RNA was produced abundantly in ATL tumor cells but not in steady-state normal cells.
21480325Hepatocellular CarcinomaPromote immunityThe TAAs consisting of cyclophilin B, squamous cell carcinoma antigen recognized by T cells (SART) 2, SART3, p53, multidrug resistance-associated protein (MRP) 3, alpha-fetoprotein (AFP) and human telomerase reverse transcriptase (hTERT) were frequently recognized by T cells and these TAA-derived peptides were capable of generating peptide-specific CTLs in HCC patients, which suggested that these TAAs are immunogenic. Cyclophilin B, SART2, SART3, p53, MRP3, AFP, and hTERT were immunogenic targets for HCC immunotherapy.
20130242B16 Malignant Melanoma; HLA-A2.1 MelanomaPromote immunityTargeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Compared with peptide-based vaccinations, the lv-hTERT vector triggers better and more sustained CD8(+) T-cell response against self/TERT epitope in vivo. Both primary and long-lasting self/TERT-specific CD8(+) T-cell responses induced with Iv-hTERT vector required the presence of CD4 T cells in vivo. This lv-hTERT-based active immunotherapy efficiently inhibits the growth of telomerase expressing tumors (B16/HLA-A2.1 murine melanoma) in HHD mice. These data show that targeting hTERT with lentivector is highly effective in stimulating a broad range of CD8 T-cell immunity that can be exploited for cancer immunotherapy.
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TERT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.61; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TERT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0210.927
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0960.833
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0380.917
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1980.742
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5020.685
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1830.904
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3420.695
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.2970.32
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.2760.114
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0580.876
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0580.92
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4890.0533
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TERT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TERT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TERT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TERT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TERT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TERT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TERT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTERT
Nametelomerase reverse transcriptase
Aliases TRT; hEST2; EST2; CMM9; DKCA2; DKCB4; PFBMFT1; hTRT; telomerase catalytic subunit; telomerase-associated pro ......
Chromosomal Location5p15.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TERT collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TERT.
ID Name Drug Type Targets #Targets
DB00495ZidovudineSmall MoleculeTERT1
DB05036Grn163lSmall MoleculePTGES3, SCYL1, SMG6, TERT4
DB12747TertomotideBiotechTERT1